Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Antipsychotic/Risperidone Consta; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Butner, North Carolina • Durham, North Carolina

Conditions: Psychosis, Psychosis Nos/Other, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Prodromal Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders, Schizophreniform Disorders, Major Depression With Psychotic Features, Unspecified Psychosis, Bipolar Disorder
Interventions: Cognitive and Social Cognitive Training, Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App, Early Psychosis Coordinated Specialty Care; Device · Behavioral · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 40 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychosis NOS
Interventions: Risperidone, Omega-3 capsules, Placebo; Drug
Lead sponsor: Delbert Robinson; Other
Eligibility: 15 Years to 40 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions: Coordinated Specialty Care (CSC); Other
Lead sponsor: Indiana University; Other
Eligibility: 16 Years to 35 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more

Conditions: Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: BXCL501, Matching Placebo; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 24
States / cities: Bellflower, California • Cerritos, California • Culver City, California + 19 more

Conditions: Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions: Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years to 35 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: Sublingual film containing dexmedetomidine (BXCL501), Placebo Film; Drug
Lead sponsor: BioXcel Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 15
States / cities: Little Rock, Arkansas • Cerritos, California • Culver City, California + 12 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: Not listed
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 12 Years to 80 Years
Enrollment: 837 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions: Sibutramine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 16
States / cities: El Centro, California • Jacksonville, Florida • Miami, Florida + 13 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Betahistine, Placebo Oral Tablet; Drug
Lead sponsor: Nathan Kline Institute for Psychiatric Research; Other
Eligibility: 18 Years to 59 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more

Conditions: Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder
Interventions: ALKS 3831; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 49
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 40 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions: Latuda©; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 19 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
Interventions: quetiapine, olanzapine, risperidone; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions: Clubhouse Model of Psychosocial Rehabilitation for Serious Mental Illness, Usual Community-Based Mental Health Care; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 19 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders, Psychosis Nos/Other
Interventions: iTBS (Active), iTBS (Sham); Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia
Interventions: Risperidone, Olanzapine (enrollment closed in this treatment), Molindone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 8 Years to 19 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 4
States / cities: Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions: Integrated Metacognitive Therapy, Treatment as Usual; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: zonisamide SR plus olanzapine, Placebo plus olanzapine; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 9
States / cities: National City, California • Orange, California • San Diego, California + 6 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder Not Otherwise Specified
Interventions: long-acting injectable risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Brooklyn, New York • Glen Oaks, New York

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions: Horyzons USA; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 35 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

EPI-MINN: Targeting Cognition and Motivation - National

Omega-3 Dietary Supplements in Schizophrenia

Academic-Community EPINET (AC-EPINET)

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

Minnesota Community-Based Cognitive Training in Early Psychosis

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

Brain Circuits in Schizophrenia and Smoking

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

A Comparative Study of New Medications for Psychosis in Adolescents

REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

iTBS to Enhance Social Cognition in People With Psychosis

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Integrated Metacognitive Therapy in First Episode Psychosis

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Optimizing Response in Psychosis Study

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

Horyzons: Implementation in Clinical Practice